on AMOEBA (EPA:ALMIB)
Amoéba's 2025 Annual Results: Towards commercialization in 2026
On February 23, 2026, Amoéba presented its 2025 annual results, marked by regulatory advancements and intense commercial preparation. The company, a specialist in amoeba-based microbiological solutions, obtained approval for its active substance in Europe and commercial authorization in the United States for its biocontrol product AXPERA. These advancements pave the way for commercialization planned for 2026.
The agreements with Koppert and Syngenta, as well as the awards received, strengthen its credibility. Amoéba invested more heavily in industrial development, impacting a net loss of €8,303,000. The company plans to continue operating until the end of 2026, with guaranteed financial support.
In the cosmetics sector, an agreement has been signed with Oriental Beauty Valley in China, strengthening its position in this market. 2026 is expected to mark the beginning of a gradual commercial expansion for Amoéba.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news